Humacyte (HUMA) Liabilities and Shareholders Equity (2020 - 2026)

Humacyte (HUMA) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $110.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 31.99% year-over-year to $110.6 million; the TTM figure through Mar 2026 stood at $457.2 million (down 17.39% YoY), while the FY2025 annual figure was $116.4 million, down 15.6% from the prior year.
• Liabilities and Shareholders Equity slipped to $110.6 million in Q1 2026 per HUMA's latest filing, from $116.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $264.5 million in Q1 2022 and bottomed at $91.5 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $161.3 million across 5 years, with a median of $149.4 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 162.71% — and 2023, when it plunged 37.24%.
• Humacyte's Liabilities and Shareholders Equity stood at $204.3 million in 2022, then slumped by 37.24% to $128.2 million in 2023, then advanced by 7.53% to $137.9 million in 2024, then retreated by 15.6% to $116.4 million in 2025, then declined by 4.99% to $110.6 million in 2026.
• Business Quant data shows HUMA's Liabilities and Shareholders Equity at $110.6 million in Q1 2026, $116.4 million in Q4 2025, and $91.5 million in Q3 2025.